Document Detail

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.
MedLine Citation:
PMID:  22294554     Owner:  NLM     Status:  Publisher    
BACKGROUND: Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving the interval is superior to doubling the dose. We aimed to assess the efficacy of infliximab dose intensification by interval-halving compared with dose-doubling. METHODS: A multicenter retrospective study of CD patients losing response to infliximab was undertaken. The clinical outcome of patients whose infusion intervals were halved (5 mg/kg/4 weeks) was compared with patients treated by dose-doubling (10 mg/kg/8 weeks). RESULTS: In all, 168 patients were included from 18 centers in Europe, USA, and Israel. Of these, 112 were intensified by dose-doubling and 56 received interval-halving strategy. Early response to dose-escalation was experienced by 86/112 (77%) patients in the dose-doubling group compared with 37/56 patients (66%) in the interval-halving group (odds ratio [OR] 1.7, 95% confidence interval [CI] 0.8-3.4, P = 0.14). Sustained clinical response at 12 months postescalation was maintained in 50% of patients in the dose-doubling group compared with 39% in the interval-halving group (OR 1.5, 95% CI 0.8-2.9, P = 0.2). On multivariate analysis, predictors of long-term response to escalation were a nonsmoking status, CD diagnosis between 16-40 years of age, and normal C-reactive protein (CRP). CONCLUSIONS: Dose intensification leads to a sustained regained response in 47% of CD patients who lost response to standard infliximab dose, but halving the infusion intervals is probably not superior to dose-doubling. Given the costs and patient inconvenience incurred by an additional infusion visit, the dose-doubling strategy may be preferable to the interval-halving strategy. (Inflamm Bowel Dis 2012;).
Lior Katz; Javier P Gisbert; Beth Manoogian; Kirk Lin; Casper Steenholdt; Gerassimos J Mantzaris; Ashish Atreja; Yulia Ron; Arun Swaminath; Somal Shah; Ailsa Hart; Peter Laszlo Lakatos; Pierre Ellul; Eran Israeli; Mads Naundrup Svendsen; C Janneke van der Woude; Konstantinos H Katsanos; Laura Yun; Epameinondas V Tsianos; Torben Nathan; Maria Abreu; Iris Dotan; Bret Lashner; Jorn Brynskov; Jonathan P Terdiman; Peter D R Higgins; Maria Chaparro; Shomron Ben-Horin
Related Documents :
1105694 - The effect of prostaglandin f2beta on expiratory flow rates.
2782734 - Tachyphylaxis to systemic but not to airway responses during prolonged therapy with hig...
22515204 - A clinical audit of antithrombin concentrate use in a tertiary paediatric centre.
18044104 - Effect of bronchodilatation on single breath pulmonary uptake of carbon monoxide in chr...
8065234 - Glutamine protects chinese hamster ovary cells from radiation killing.
25411294 - Bioavailability of enteric-coated microencapsulated calcium during pregnancy: a randomi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-31
Journal Detail:
Title:  Inflammatory bowel diseases     Volume:  -     ISSN:  1536-4844     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-2-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508162     Medline TA:  Inflamm Bowel Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Gastroenterology Department, Sheba Medical Center, Tel Hashomer, Tel-Aviv University, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma a...
Next Document:  Combined adverse effects of maternal smoking and high body mass index on heart development in offspr...